Skip Navigation

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
NIH HHS News Release Logo

National Institute of Allergy and
Infectious Diseases (NIAID)

Wednesday, August 6, 2003

Media Contact:
Jeff Minerd
(301) 402-1663
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Fast-Acting Ebola Vaccine Protects Monkeys

A single shot of a fast-acting, experimental Ebola vaccine successfully protects monkeys from the deadly virus after only one month. If this vaccine proves similarly effective in humans, it may one day allow scientists to quickly contain Ebola outbreaks with ring vaccination—the same strategy successfully used in the past against smallpox, according to a study published in this week’s issue of Nature

This finding is the result of collaboration between scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), and scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, MD.

“This research has enormous public health implications not only because it might be used to limit the spread of Ebola virus, which continues to emerge in central Africa, but also because this vaccine strategy may be applied to other highly lethal viruses, such as the Marburg and Lassa fever viruses and the SARS coronavirus, that cause acute disease outbreaks and require a rapid response,” says NIAID Director Anthony S. Fauci, M.D.

Under the directorship of Gary Nabel, M.D., Ph.D., scientists at the VRC have been pursuing the so-called “prime-boost” vaccine strategy against a variety of infectious diseases. Prime-boost is a two-part process: First, an injection of non-infectious genetic material from the disease-causing microbe primes the immune system to respond. Second, several weeks later, an injection of attenuated carrier viruses containing key genes from the microbe substantially boosts the immune response.

The VRC scientists found that the boost alone produces a quicker but weaker immune response as compared with the prime-boost strategy. Knowing that time is critical when fighting Ebola, the scientists decided to test whether the boost’s fast response was strong enough on its own to protect against the disease. To perform this test, they collaborated with colleagues at USAMRIID, who had the necessary facilities and expertise and who had developed good animal models for the experiment.

The VRC scientists immunized eight monkeys with a single boost injection, consisting of attenuated carrier viruses containing genes for important Ebola antigens. The monkeys were then delivered to USAMRIID where they were injected with an Ebola virus strain obtained from a fatally infected person from the former Zaire in 1995. The single vaccine injection completely protected all eight animals against Ebola infection, even those who received high doses of the virus.

“I am proud that our research team at USAMRIID was able to form an effective partnership with our colleagues at NIAID to develop and evaluate this Ebola vaccine,” comments Peter B. Jahrling, Ph.D., senior research scientist at USAMRIID. “After years of developing candidate Ebola vaccines that protected rodents but failed in primates, it is gratifying to have a vaccine that holds great promise for protection of humans. Eventually, this vaccine may reduce the hazard of working with Ebola virus in the laboratory, as well as provide protection to populations at risk of natural exposure."

Ebola virus spreads easily from person to person, causes illness quickly and kills a significant number of the people it infects. There is no treatment for the disease, so preventing the spread of the virus is key to containing outbreaks. If the results of this animal study hold true for humans, the new vaccine may be just the Ebola-fighting tool that public health officials need during epidemic outbreaks, Dr. Nabel explains.

“Ring vaccination might be used to stop the spread of the Ebola virus during acute outbreaks, just as this strategy was used to contain smallpox in the past,” Dr. Nabel says. With ring vaccination, everyone who has been in contact with a patient, as well as all members of the patient’s household, are vaccinated. The ring strategy, which requires a fast-acting vaccine, not only protects people who may have been exposed to the virus but also creates an added barrier of immunity around them, thereby protecting the entire community.

Even though the boost alone appears to be effective, the prime-boost strategy, which requires four shots over six months, will still be important to pursue as well, Dr. Nabel says. “The prime-boost strategy elicits a stronger immune response,” he explains, “and it may be useful for preventive vaccines intended for hospital workers at high risk of exposure to the virus, for example.”




N Sullivan et al. Accelerated vaccine for Ebola virus hemorrhagic fever in non-human primates. Nature 424(6949):681-84 (2003).

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health ®

back to top


NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.

Last Updated August 06, 2003